GlaxoSmithKline got its first taste of synthetically lethal cancer therapies via an acquisition. Now it’s trying for a bigger bite of this emerging drug
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering. In addition, IDEAYA intends
The California-based company is developing drugs that work through "synthetic lethality," whereby they target two genes at once rather than only targeting one.

P/E Ratio Insights for IDEAYA Biosciences

02:54pm, Tuesday, 16'th Jun 2020
In the current session, IDEAYA Biosciences Inc. (NASDAQ: IDYA) is trading at $12.31, after a 37.60% spike. Over the past month, the stock increased by 58.60%, and in the past year, by 14.66%. With per
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) * Applied Molecular Transport Inc (NASDAQ: AMTI) (wen
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology.
In this article we will take a look at whether hedge funds think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a good investment right now. We check hedge fund and billionaire investor sentiment before de
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE